BioStem Technologies annual current ratio
2021
2022
2023
2024
2025
BioStem Technologies Current Ratio Growth & History (BSEM)
BioStem Technologies's current ratio was 4.12 for fiscal 2025.
View full BioStem Technologies company overviewBioStem Technologies annual current ratio history
| Fiscal year | Period ended | Current ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 4.12 | 1.23 | +42.57% |
| 2024 | 2024-12-31 | 2.89 | 2.08 | +258.09% |
| 2023 | 2023-12-31 | 0.81 | 0.57 | +243.35% |
| 2022 | 2022-12-31 | 0.23 | 0.09 | +63.70% |
| 2021 | 2021-12-31 | 0.14 | — | — |
BioStem Technologies quarterly current ratio
Q4.24
Q3.25
Q4.25
Q2.26
| Fiscal quarter | Period ended | Current ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 0.98 | — | — |
| Q4 2025 | 2025-12-31 | 4.12 | 2.77 | +205.28% |
| Q3 2025 | 2025-09-30 | 4.31 | — | — |
| Q4 2024 | 2024-12-31 | 1.35 | — | — |
BioStem Technologies current ratio trends
Between the periods ended 2021-12-31 and 2025-12-31, BioStem Technologies's current ratio increased from 0.14 to 4.12, a change of 3.97. The latest reported quarter, Q2 2026, shows 0.98.
About the metric
What the current ratio means
The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.
Calculation and source
How the current ratio is calculated
TickerStat calculates the current ratio as SEC-reported current assets divided by SEC-reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review BioStem Technologies source filings ↗